Evidence-based articles, treatment guides, and the latest news in addiction recovery and mental health.
CDC provisional data shows 69,147 predicted overdose deaths for the 12 months ending January 2026, a 13.2% decline as naloxone access and treatment expansion show measurable impact.
Virginia Opioid Abatement Authority announces largest funding round to date, supporting prevention, treatment, recovery and harm reduction initiatives across the Commonwealth.
Super-potent synthetic opioids called nitazenes are flooding the U.S. drug supply, causing hundreds of deaths and overwhelming harm reduction efforts.
State insurance regulators find Aetna, Anthem, Cigna, ConnectiCare, and UnitedHealthcare systematically underpaid mental health providers and restricted access to care.
Researchers create a new class of compounds that activate serotonin receptors linked to brain healing without causing hallucinations, potentially opening addiction treatment to broader populations.
MSDH becomes one of few state health departments offering direct clinic-based SUD care, using technology to identify risk earlier and reduce barriers.
New NIH-funded research shows oral GLP-1 drugs like orforglipron reach the central amygdala, opening potential pathways for treating substance use disorders.
Law enforcement reports fentanyl increasingly combined with xylazine, medetomidine, nitazenes and cychlorphine—substances that resist naloxone reversal.
First randomized double-blind study in Sweden finds psilocybin provides clinically meaningful depression relief within days, with 53% remission rate at six weeks.